Noradrenaline Reuptake Inhibition Enhances the Antipsychotic-like Effect of Raclopride and Potentiates D2-blockage–induced Dopamine Release in the Medial Prefrontal Cortex of the Rat

摘要: We have previously observed that addition of an α2-adrenoceptor antagonist to a selective dopamine (DA) D2 receptor enhances the antipsychotic-like effect blocker and also selectively increases DA output in medial prefrontal cortex (mPFC) rats. These data correlate well with previous clinical trials showing augmentation by equivalent drug combination schizophrenia. Since noradrenaline reuptake inhibitor reboxetine was found cause similar effects on mesolimbocortical system as antagonists, present study undertaken explore whether might augment raclopride same preclinical model antipsychotic activity, conditioned avoidance response (CAR) test. investigated this catalepsy test for extrapyramidal side liability, mPFC nucleus accumbens, respectively. Reboxetine (6 mg/kg, i.p.) significantly enhanced suppressant (0.1 s.c.) CAR without affecting catalepsy. Administration rats pretreated resulted greatly but not accumbens when compared alone. Consequently, these results suggest inhibition may provide means augmenting efficacy classical D2-antagonists treatment schizophrenia, and, principle, generate atypical profile.